HC Berlin Pharma AG
Cofounder of SAP AG Hasso Plattner invests in HC Berlin Pharma AG
HC Berlin Pharma AG / Contract Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Berlin, October 28, 2008 – HC Berlin Pharma AG today announced that Hasso Plattner, cofounder and Chairman of the Supervisory Board of SAP AG, took a shareholding of € 5 million in HC Berlin Pharma AG based on a property contract, whereby HC Berlin Pharma AG buys his 17,000 sqm building incl. the 21,000 sqm freehold in the Science Park Golm in Potsdam, next to Max Planck Institute and Fraunhofer Institute for shares and cash. Hasso Plattner was represented by Senator Gerhard Burkhardt from PB Group, and together with Mr. Rudolf W. Schoetteldreier, Chairman of HC Berlin Pharma AG's supervisory board, and HC Berlin Pharma AG CEO Mr. Ottmar W. Geiger they signed the transaction papers. 'We are very pleased with this agreement which marks the beginning of a promising relationship', says Ottmar W. Geiger. 'We consider this transaction as an important milestone for our company and yet another important step for HC Berlin Pharma AG to successfully establish itself in the market', continues Rudolf W. Schoetteldreier. The new building of HC Berlin Pharma AG for research and development, quality control and production in the Science Park Golm is now 90 % completed. HC Berlin Pharma AG has contracted Heidelberg Pharma Consult, the pharmaceutical plant and laboratory Contract Company, who delivered already the planning documentation for laboratories, pharmaceuticals factory incl. filling plants, packing systems, logistics, R&D Lab, Quality Assurance and Administration for the setup. In the first step HC Berlin Pharma AG will use about 50 % of the total available space of 17,000 sqm usable area. The top floors for administration are ready to be equipped. Further information about HC Berlin Pharma AG can be found at www.hcberlinpharma.ag. For detailed information please contact our Investor Relations team directly at: esVedra consulting GmbH t: +49. 89. 28 80 81 33 f: +49. 89. 28 80 81 49 info@esvedra-consulting.com www.esvedra-consulting.com About HC Berlin Pharma AG HC Berlin Pharma AG is a pharmaceutical company listed on the Open Market of the Frankfurt Stock Exchange, which develops and will manufacture at its headquarter in Berlin pharmaceutical and medical technology solutions. HC Berlin Pharma AG was formed in May 2007 and develops new ways of administering active agents that have already been tested and that promise greater effectiveness and healing power. The flagship product is ArTiMist™, an anti-malaria drug specially developed for children and administered as a sublingual spray. With NiCoSorb™, a nicotine replacement therapy, HC Berlin Pharma AG offers another aerosol spray. In the field of medical technology HC Berlin Pharma AG offers systems for risk-free injections and the taking of blood samples: ClipOn™ is the name of the brand for human medicine; in the market for veterinary medicine this product is called VetLok™. A further product group from the field of medical technology are sterile wraps and pocket packaging under the MediSheet™ trademark. Furthermore, HC Berlin Pharma AG has specialised on tamper evident and child resistant packaging. Disclaimer This announcement is intended solely for general purposes and in no way implies an invitation to buy or sell the shares of HC Berlin Pharma AG. 28.10.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found